Prediction of recurrence by quantification of p185(neu) protein in non-small cell lung cancer tissue

British Journal of Cancer

Volumn 75, Issue 5, 1997, Pages 684-689

  Diez, M ^a,c   Pollan M ^b   Maestro, M ^a   Torres, A ^a   Ortega, D ^a   Gomez A ^a   Sanchez A ^a   Hernando, F ^a   Balibrea, J L ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b CARLOS III INSTITUTE OF HEALTH   (Spain)

^c HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

c erbB 2; Lung cancer; Oncogene; p185; Prognostic factors

Indexed keywords

ONCOPROTEIN;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; DIAGNOSTIC TEST; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS;

EID: 0031051221     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.122     Document Type: Article

References (23)

1. Bongiorno PF, Whyte RI, Lesser EJ, Moore JH, Orringer MB and Beer DG (1994) Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas. J Thorac Cardiovasc Surg 107: 590-595
2. Breslow NE and Day NE (1987) Statistical Methods in Cancer Research Vol. II. The Design and Analysis of Cohort Studies IARC Scientific Publication No. 82: IARC: Lyon
3. Coussens L, Yang-Feng TL, Liao YC, Chen-dray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Franke V, Levinson A and Ullrich A (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132-1139
4. Cox DR Regression models and life tables (with discussion) (1972) J R Stat Soc B 34: 187-220
5. Cuny M, Simony-Lafontaine J, Rouanet P, Grenier J, Valles H, Lavaille R, Lorasen G, Causse A, Lequeux N and Thierry C (1994) Quantification of ERBB2 protein expression in breast cancer: three levels of expression defined by their clinico-pathological correlations. Oncol Res 6: 169-176
6. Drebrin JA, Stern AF, Link VC, Weinberg RA and Greene MI (1984) Monoclonal antibodies identify a cell surface antigen associated with an activated cellular oncogene. Nature 312: 545-548
7. Dittadi R, Donisi PM, Brazzale A, Marconato R, Spina M and Gion M (1992) Immunoenzymatic assay of erbB2 protein in cancer and non-malignant breast tissue. Relationship with clinical and biochemical parameters. Anticancer Res 12: 2005-2010
8. Fielding LP, Fenoglio-Preiser CM and Freedman LS (1992) The future of prognostic factors in outcome prediction for patients with cancer. Cancer 70: 2367-77
9. Fukushige S, Matsubara K, Yoshida M, Sasaki M, Suzuki T and Semba K (1986) Localization of a novel v-erbB-related gene. c-erbB-2 on human chromosome 17 and its amplification in a gastric cell line. Mol Cell Biol 6: 955-958
10. Harpole DA, Herndon JE, Wolfe W, Iglehart JD and Marks JR (1995) A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 55: 51-56
11. Kern JA, Schwartz DA, Nordberg JE, Weiner D, Greene MI, Torney L and Robinson RA (1990) P185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50: 5184-5191
12. Kern JA, Slebos R, Top B, Rodenhuis S, Lager D, Robinson RA, Weiner D and Schwartz DA (1994) C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 93: 516-520
13. Mekenzie SJ, Marks PJ, Lam T, Morgan J, Panicalli D, Trimple K and Carney W (1989) Generation and characterization of monoclonal antibodies specific for the human oncogene product. p185. Oncogene 4: 543-548
14. Miller RG (1981) Survival Analysis John Wiley & Sons: New York
15. Mountain CF (1986) A new international staging system for lung cancer. Chest 89: 225S-233S
16. Narita T, Funahashi H, Satoh Y, Imal T and Takagi H (1994) Quantitative analysis of c-erbB-2 protein in breast cancer tissue by enzyme immunoassay. Jpn J Clin Oncol 24: 74-78
17. Nugzent A, Gallagher J, Dolan J, O'Higgins N and Duffy MJ (1994) Assay of the c-erbB-2 oncogene encoded protein by ELISA and immunocytochemistry in human breast cancer. Ann Clin Biochem 31: 171-173
18. Shi D, Gongping H, Shilong C, Pan W, Zhang HZ, YU D and Hung MC (1992) Overexpression of the c-erbB-2/neu encoded p185 protein in primary lung cancer. Mol Carcinogen 5: 213-218
19. Stern DF, Hefferman PA and Weinberg R (1986) p185: a product of the neu protooncogene. is a receptor-like protein associated with tyrosine kinase activity. Mol Cell Biol 6: 1729-1740
20. Tateishi M, Ishida T, Mitsudomi T, Kaneko S and Sugimachi K (1991) Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 27: 1372- 1375
21. Tsai CM, YU D, Chang KT, WU LH, Perng RP, Ibrahim NK and Hung MC (1995) Enhanced chemoresistance by elevation of p185neu levels in HER-2/neutransfected human lung cancer cells. J Natl Cancer Inst 87: 682-684
22. Weiner DB, Nordberg J, Robinson R, Nowell PC, Gazdar A, Greene MI, Williams WV, Cohen JA and Kern JA (1990) Expression of the neu gene-encoded protein (p185neu) in human non-small cell carcinomas of the lung. Cancer Res 50: 421-425
23. World Health Organization (1982) Histologic typing of lung tumors. Am J Clin Pathol 77: 123-136